Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Q4 2024 Earnings Call Transcript March 5, 2025 Kamada Ltd. beats earnings expectations. Reported EPS is $0.07, expectations ...

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearanceStrategic partnership with Orano Med on ...

Good afternoon and welcome to Marvell Technology, Inc.'s Fourth Quarter and Fiscal Year 2025 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After ...

Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of ...

In February 2025, Atea appointed Arthur S. Kirsch to the Company's Board of Directors. Mr. Kirsch has decades of experience ...

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated ...

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides ...

American Public Education, Inc. , a portfolio of education companies providing online and campus-based postsecondary education and career learning to over 125,000 students through four subsidiary ...